Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Antipodocalyxin Antibody chPcMab-47 Exerts Antitumor Activity in Mouse Xenograft Models of Colorectal Adenocarcinomas.

Kaneko MK, Kunita A, Yamada S, Nakamura T, Yanaka M, Saidoh N, Chang YW, Handa S, Ogasawara S, Ohishi T, Abe S, Itai S, Harada H, Kawada M, Nishioka Y, Fukayama M, Kato Y.

Monoclon Antib Immunodiagn Immunother. 2017 Aug;36(4):157-162. doi: 10.1089/mab.2017.0020. Epub 2017 Jun 30.

PMID:
28665782
2.

ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.

Kaneko MK, Nakamura T, Kunita A, Fukayama M, Abe S, Nishioka Y, Yamada S, Yanaka M, Saidoh N, Yoshida K, Fujii Y, Ogasawara S, Kato Y.

Monoclon Antib Immunodiagn Immunother. 2017 Jun;36(3):104-112. doi: 10.1089/mab.2017.0014. Epub 2017 May 15.

PMID:
28504613
3.

Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.

Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y.

Cancer Med. 2017 Apr;6(4):768-777. doi: 10.1002/cam4.1049. Epub 2017 Mar 23.

4.

Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.

Kato Y, Kunita A, Fukayama M, Abe S, Nishioka Y, Uchida H, Tahara H, Yamada S, Yanaka M, Nakamura T, Saidoh N, Yoshida K, Fujii Y, Honma R, Takagi M, Ogasawara S, Murata T, Kaneko MK.

Monoclon Antib Immunodiagn Immunother. 2017 Feb;36(1):20-24. doi: 10.1089/mab.2016.0045.

PMID:
28234556
5.

The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.

Kato Y, Kunita A, Abe S, Ogasawara S, Fujii Y, Oki H, Fukayama M, Nishioka Y, Kaneko MK.

Oncotarget. 2015 Nov 3;6(34):36003-18. doi: 10.18632/oncotarget.5339.

6.

Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity.

Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y.

Cancer Sci. 2012 Nov;103(11):1913-9. doi: 10.1111/j.1349-7006.2012.02385.x. Epub 2012 Aug 27.

7.

Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.

Kato Y, Kaneko MK, Kunita A, Ito H, Kameyama A, Ogasawara S, Matsuura N, Hasegawa Y, Suzuki-Inoue K, Inoue O, Ozaki Y, Narimatsu H.

Cancer Sci. 2008 Jan;99(1):54-61. Epub 2007 Oct 18.

8.

The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis.

Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, Tsuruo T, Fujita N.

Am J Pathol. 2007 Apr;170(4):1337-47.

9.

Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma.

Mishima K, Kato Y, Kaneko MK, Nakazawa Y, Kunita A, Fujita N, Tsuruo T, Nishikawa R, Hirose T, Matsutani M.

Acta Neuropathol. 2006 Jun;111(6):563-8. Epub 2006 May 5.

PMID:
16718353
10.

Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/Podoplanin) molecules expressed in Chinese hamster ovary cells.

Kaneko M, Kato Y, Kunita A, Fujita N, Tsuruo T, Osawa M.

J Biol Chem. 2004 Sep 10;279(37):38838-43. Epub 2004 Jul 1.

11.

Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors.

Kato Y, Fujita N, Kunita A, Sato S, Kaneko M, Osawa M, Tsuruo T.

J Biol Chem. 2003 Dec 19;278(51):51599-605. Epub 2003 Oct 1.

Supplemental Content

Loading ...
Support Center